|1.||Montorsi, Francesco: 17 articles (06/2008 - 05/2004)|
|2.||Vardenafil Study Group: 16 articles (04/2008 - 04/2003)|
|3.||Porst, Hartmut: 10 articles (07/2008 - 09/2003)|
|4.||Sandner, Peter: 9 articles (01/2015 - 12/2006)|
|5.||Maggi, Mario: 9 articles (01/2014 - 03/2007)|
|6.||Hellstrom, Wayne J G: 9 articles (02/2013 - 11/2002)|
|7.||Eardley, Ian: 9 articles (09/2011 - 11/2004)|
|8.||Beneke, Manfred: 8 articles (10/2011 - 07/2004)|
|9.||Ulbrich, Ernst: 8 articles (10/2011 - 07/2004)|
|10.||Rosen, Raymond C: 8 articles (02/2010 - 01/2003)|
01/01/2011 - "Vardenafil is a potent and highly selective oral phosphodiesterase type 5 (PDE-5) inhibitor that has been shown in numerous clinical trials and post-marketing surveillance studies to be safe and effective for improving erectile function in men with erectile dysfunction (ED). "
01/01/2006 - "Vardenafil was well tolerated and highly efficacious in men with erectile dysfunction and untreated mild major depression. "
07/01/2004 - "Vardenafil is a selective and highly potent phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED), with improved selectivity for PDE5 and demonstrated efficacy for improving sexual function in men with ED. "
01/01/2012 - "The efficacy of on-demand vardenafil ODT 10 mg was established in the POTENT I and II studies, which were 6-week, randomized, double-blind, multinational trials in men with erectile dysfunction of at least 6 months duration. "
06/01/2005 - "In this difficult to treat population of men with erectile dysfunction subsequent to NS-RRP on demand treatment with vardenafil during a 3-month period significantly improved key aspects of the sexual experience important to patient quality of life."
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
01/01/2009 - "Stief, Hartmut Porst, Dieter Neuser, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. "
06/01/2008 - "A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia."
07/01/2008 - "Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia."
09/01/2011 - "Placebo-controlled trials of tadalafil and vardenafil showed improvement of LUTS secondary to benign prostatic hyperplasia (BPH), but none of the studies showed a significant effect on urodynamic measures. "
06/01/2012 - "Safety and efficacy of tamsulosin and vardenafil are well established: however, there is no report regarding combined therapy with these drugs for lower urinary tract symptoms (LUTSs) secondary to benign prostatic hyperplasia (BPH). "
|3.||Hypertension (High Blood Pressure)
10/01/2008 - "Across all trials, vardenafil showed good efficacy for the treatment of ED in patients with diabetes, hypertension and dyslipidaemia. "
10/01/2008 - "The evidence presented in this review suggests that vardenafil is efficacious and well tolerated in patients with ED and diabetes, hypertension and/or dyslipidaemia and can be recommended as first-line treatment for ED in patients with these conditions."
11/01/2005 - "To investigate the safety and efficacy of flexible-dose vardenafil therapy compared with placebo in PDE5 inhibitor-naïve subjects with arterial hypertension and ED. "
10/01/2008 - "Relevant articles were identified through a PubMed search of clinical trials and postmarketing surveillance studies of vardenafil in patients with ED including those with diabetes, hypertension and dyslipidaemia. "
10/01/2007 - "Eight clinical trials were included (n = 2427 patients) consisting of 839 patients (35%) with a self-reported diagnosis of hypertension (HTN): 498 in the vardenafil and 341 in the placebo groups. "
01/01/2002 - "A 12-week trial in 452 men with ED associated with diabetes mellitus demonstrated that treatment with vardenafil 20mg compared with placebo significantly improved IIEF erectile function domain scores and the rate of positive responders to the erectile improvement GAQ. "
08/01/2006 - "The efficacy of vardenafil has been demonstrated in a broad range of ED populations, but has not yet been assessed in Japanese patients with diabetes mellitus (DM), although DM is frequently associated with difficult-to-treat ED. "
01/01/2004 - "Vardenafil improved erectile function in men with ED associated with diabetes mellitus or ED following unilateral or bilateral nerve-sparing radical retropubic prostatectomy in two randomised, double-blind, multicentre, fixed-dose, 3-month studies. "
01/01/2003 - "Vardenafil improved erectile function in men with ED associated with diabetes mellitus or ED following unilateral or bilateral nerve-sparing radical retropubic prostatectomy in two randomised, double-blind, multicentre, fixed-dose, 3-month studies. "
08/01/2006 - "Vardenafil 20-mg demonstrated superior efficacy to 10-mg in Japanese men with diabetes mellitus suffering from erectile dysfunction."
|5.||Spinal Cord Injuries (Spinal Cord Injury)
11/01/2006 - "Efficacy of vardenafil has been demonstrated in various ED populations, but that in Japanese patients with spinal cord injury (SCI) has not been assessed. "
04/01/2008 - "To assess the effect of the oral phosphodiesterase type-5 inhibitor, vardenafil, on ejaculation rates and self-confidence in men with spinal cord injury (SCI). "
11/01/2007 - "Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study."
01/24/2006 - "Vardenafil significantly improved erectile and ejaculatory function and was generally well tolerated in men with erectile dysfunction due to spinal cord injury."
04/01/2008 - "Vardenafil improves ejaculation success rates and self-confidence in men with erectile dysfunction due to spinal cord injury."
|3.||Phosphodiesterase 5 Inhibitors
|4.||Type 5 Cyclic Nucleotide Phosphodiesterases
|1.||Prostatectomy (Retropubic Prostatectomy)
|2.||Transplantation (Transplant Recipients)
|3.||Drug Therapy (Chemotherapy)
|5.||Transurethral Resection of Prostate (TURP)